Targeting Cancer of Unmet Need
Targeting Cancer of Unmet Need
Patients with cancers of unmet need are faced with limited treatment options, and poor 5-year survival rates that have not improved in recent years despite continuing advances in cancer research.
Our mission is to develop novel treatments that can be used in combination with first line therapies to improve survival outcomes and the quality of life of these patients.
New Small Molecule Therapies
Varsity partners with leading oncology academics in Cambridge, and globally, to identify new targets to address drug resistance and develop new small molecule therapies for several resistant cancers.
Varsity works to transform these novel discoveries into new therapies for patients by supporting the clinical development work needed for their eventual regulatory approval and distribution.
About us
Varsity Pharmaceuticals was founded in Cambridge in 2020 as an Oncology focused sister company to the Rare Disease focused Cycle Pharmaceuticals, both part of the Cycle Group. Varsity is ideally placed to use the Cycle Group drug development expertise to support the transformation of world leading oncology research in to life-changing treatments for cancer patients.
Visit www.cyclepharma.com to learn more about Cycle.
News
Varsity Licenses Pol-Theta Inhibitor
Varsity today announced that it has secured exclusive rights from Dana-Farber Cancer Institute to develop and commercialize Novobiocin, a potential first-in-class DNA Pol-theta inhibitor for the treatment of Homologous Recombination (HR) deficient cancers.
Pipeline
Preclinical
Clinical
Contact Info
Email Address
info@varsitypharma.com
Main Office Address
The Broers Building, 21 JJ Thomson Avenue, Cambridge, CB3 0FA, United Kingdom